Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Multiple Sclerosis Clinical Trial

Official title:

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00648908
• Other study ID #: MS-F203EXT
• Status: Completed
• Phase: Phase 3
• First received: March 28, 2008
• Last updated: February 24, 2012
• Start date: June 2006
• Est. completion date: April 2011

Study information

• Verified date: January 2012
• Source: Acorda Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.

Description:

Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 269
• Est. completion date: April 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• subject must have been previously enrolled in Acorda Therapeutics MS-F203 study for multiple sclerosis and received either Fampridine-SR or placebo

• subject is a man or woman with clinical definite multiple sclerosis as defined by McDonald (McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis; Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis; Annals of Neurology. 2001; 50: 121-127)

• subject must be at least 18 years of age. Any subject who is now over the age of 70 must be in good overall health in the judgment of the Investigator

• subject must be of adequate cognitive function, as judged by the Investigator, to understand and sign the IRB/REB-approved informed consent form prior to the performance of any study-specific procedures and is willing to comply with the required scheduling and assessments of the protocol

• subjects who are women of childbearing potential, regardless of sexual activity, must have a negative urine pregnancy test at the Screening Visit.

Exclusion Criteria:

• women who are either pregnant or breastfeeding, and women of childbearing potential (defined as not surgically sterile or at least two years post menopausal) who are engaged in active heterosexual relations and, are not using one of the following birth control methods: tubal ligation, implantable contraception device, oral, patch, injectable or transdermal contraceptive, barrier method or sexual activity restricted to vasectomized partner.

• subject discontinued prematurely from the MS-F203 study

• subject has a history of seizures or has evidence of past, or possible, epileptiform activity on an EEG

• subject has either a clinically significant abnormal ECG or laboratory value(s) at the Screening visit, as judged by the Investigator that would preclude entry into the study. ECG and laboratory results from Visit 6 or repeat results from Visit 7 of the MS-F203 study may be used as the baseline for the current study

• subject has angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator

• subject has a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet (hydroxypropyl methylcellulose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, opadry white (tablet film coating))

• subject has received an investigational drug, except for Fampridine-SR or matching placebo under protocol MS-F203, within 30 days of the Screening Visit. Subject is scheduled to enroll in an investigational drug trial at any time during this study.

• subject has a history of drug or alcohol abuse within the past year

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Fampridine-SR
Tablets, 10 mg, BID

Locations

Country	Name	City	State
Canada	Foothills Medical Center	Calgary	Alberta
Canada	River Valley Health c/o Stan Cassidy Centre for Rehabilitation	Fredericton	New Brunswick
Canada	QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site	Halifax	Nova Scotia
Canada	Ottawa Hospital General Campus	Ottawa	Ontario
Canada	University of British Columbia, Vancouver Coastal Health Research Institute	Vancouver	British Columbia
United States	Shepherd Center	Atlanta	Georgia
United States	Maryland Center for MS	Baltimore	Maryland
United States	Neurological Research Center, Inc.	Bennington	Vermont
United States	Maimonides MS Care Center	Brooklyn	New York
United States	Fletcher Allen Health Care	Burlington	Vermont
United States	CMC - Neuroscience & Spine Institute, Division of Neurology	Charlotte	North Carolina
United States	University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Ohio State University MS Center	Columbus	Ohio
United States	Wayne State University, Department of Neurology	Detroit	Michigan
United States	The Schapiro Center for MS	Golden Valley	Minnesota
United States	Advanced Neurology Specialists	Great Falls	Montana
United States	University of Texas-Houston	Houston	Texas
United States	Indiana University MS Center	Indianapolis	Indiana
United States	MS Center at Evergreen	Kirkland	Washington
United States	USC, Keck School of Medicine Health Care Consultation Center	Los Angeles	California
United States	Corinne Goldsmith Dickinson Center for MS	New York	New York
United States	Thomas Jefferson University Physicians	Philadelphia	Pennsylvania
United States	Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center	Phoenix	Arizona
United States	Allegheny General Hospital, Allegheny Neurological Associates	Pittsburgh	Pennsylvania
United States	Oregon Health & Science University, MS Center of Oregon, UHS-42	Portland	Oregon
United States	Raleigh Neurology Associates	Raleigh	North Carolina
United States	University of Rochester	Rochester	New York
United States	UC Davis	Sacramento	California
United States	Washington University School of Medicine, Div. of Rehab/Neurology	St. Louis	Missouri
United States	SUNY Stony Brook	Stony Brook	New York
United States	Gimbel MS Center at Holy Name Hospital	Teaneck	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Acorda Therapeutics

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summary of Treatment Emergent Adverse Events (TEAE).	All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.	up to 5 years	No
Secondary	Timed 25 Foot Walk (T25FW)		Week 2, 14, 26, continuing every 26 weeks until the Final Visit	No
Secondary	Subject Global Impression (SGI)	Patients asked to complete a Subject Impression questionnaire rating his/her impression of the effects of study drug during the preceding week, specifically in regards to signs and symptoms associated with Multiple Sclerosis (MS).; For the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.	visit 1 and every clinic visit	No
Secondary	Clinician Global Impression of Change (CGIC)	Investigator's overall impression of the patients neurological status and general state of health related to his/her participation in the study; specifically signs and symptoms associated with MS.; The potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.	visit 1 and every clinic visit	No
Secondary	Expanded Disability Status Scale (EDSS)	Each patient, based on their baseline neurological exam, are scored according to the EDSS; The EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death) at the Screening Visit, Visit 6, and Final Visit or Early Termination Visit if applicable.	Screening visit, visit 6 and every 24 months thereafter	No

External Links

•   (Click here for more information about Fampridine-SR clinical trials)